Halozyme Therapeutics (HALO) Other Working Capital Changes (2010 - 2026)

Halozyme Therapeutics (HALO) has 7 years of Other Working Capital Changes data on file, last reported at $2.6 million in Q4 2023.

• On a quarterly basis, Other Working Capital Changes rose 213.81% year-over-year to $2.6 million in Q4 2023; TTM through Dec 2024 was $2.4 million, a N/A change from a year earlier, with the FY2022 full-year figure at -$2.5 million, down 83033.33% from the prior year.
• Other Working Capital Changes for Q4 2023 stood at $2.6 million, up from -$175000.0 in the prior quarter.
• Over the last five years, Other Working Capital Changes for HALO reached as high as $43.5 million in Q2 2024 and fell as low as -$38.5 million in Q3 2024.
• Historically, Other Working Capital Changes has averaged $2.5 million across 5 years, with a median of $1.2 million in 2023.
• Across the five-year window, Other Working Capital Changes jumped 650.0% in 2019 and plunged 16500.0% in 2021, its largest moves.
• Year by year, Other Working Capital Changes stood at -$6000.0 in 2019, then soared by 50.0% to -$3000.0 in 2020, then soared by 33233.33% to $994000.0 in 2021, then slumped by 327.97% to -$2.3 million in 2022, then surged by 213.81% to $2.6 million in 2023.
• Per Business Quant data, the three most recent Other Working Capital Changes figures were $2.6 million in Q4 2023, -$175000.0 in Q3 2023, and -$2.4 million in Q2 2023.